Osteoarthritis Drugs Market

Global Osteoarthritis Drugs Market Size, Share & Trends Analysis Report, By Drugs (Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs, Hyaluronic Acid Injection, and Others), By Anatomy (Ankle, Hip, Knee, Shoulder, and Others), Forecast (2021-2027)

Published: Jan 2022 | Report Code: OMR2025576 | Category : Pharmaceuticals | Delivery Format: /

The global osteoarthritis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Osteoarthritis is defined as a progressive degenerative disease of joints, caused due to breakdown and eventual loss of the cartilage of one or more joints. Pain relievers such as oral analgesics (acetaminophen and NSAIDs such as ibuprofen, naproxen, tramadol, opiates, and duloxetine), topical agents (such as capsaicin and topical NSAIDs), intra-articular agents (such as corticosteroids and hyaluronic acid), and nutraceuticals (glucosamine and chondroitin) are the widely used medication alternatives. 

The market growth is majorly attributed owing to the growing geriatric population that is prone to osteoarthritis. Further, the growing awareness about health is also projected to offer growth opportunities for the market during the forecast period.  OTC and prescription NSAIDs are extensively used to relieve pain in osteoarthritis patients. According to a study published by the National Center for Biotechnology Information (NCBI) in 2019, more than 50% of osteoarthritis patients in the US were prescribed NSAIDs. Such a considerable target population consuming these drugs is anticipated to offer growth opportunities for the market.  

Some key players operating in the market include Sanofi S.A., GlaxoSmithKline plc, and Pfizer Inc., among others. These players are focusing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships, collaborations, new product launches and development in the existing product portfolio, and so on. Further, the rising R&D activities related to drug development coupled with the growth in the funding from private as well as government organizations and research centers, and the growing cell-based research activities are the key trends observed in the market. For instance, in 2018, the Journal of Stem cells International announced a new approach for the treatment of osteoarthritis by mesenchyme stem cell therapy.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape:  Sanofi S.A., GlaxoSmithKline plc, and Pfizer Inc., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Osteoarthritis Drugs Market Report by Segment

By Drugs 

Corticosteroids

Non-Steroidal Anti-Inflammatory Drugs 

Hyaluronic Acid Injection

Others

By Anatomy

Ankle

Hip

Knee

Shoulder

Others

Global Osteoarthritis Drugs Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World